Cerebrospinal Fluid Early Fungicidal Activity as a Surrogate Endpoint for Cryptococcal Meningitis Survival in Clinical Trials
- 8 January 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 71 (7) , e45-e49
Abstract
In cryptococcal meningitis phase 2 clinical trials, early fungicidal activity (EFA) of Cryptococcus clearance from cerebrospinal fluid (CSF) is used as a surrogate endpoint for all-cause mortality. The Food and Drug Administration allows for using surrogate endpoints for accelerated regulatory approval, but EFA as a surrogate endpoint requires further validation. We examined the relationship between rate of CSF Cryptococcus clearance (EFA) and mortality through 18 weeks. We pooled individual-level CSF data from 3 sequential cryptococcal meningitis clinical trials conducted during 2010–2017. All 738 subjects received amphotericin + fluconazole induction therapy and had serial quantitative CSF cultures. The log10-transformed colony-forming units (CFUs) per mL CSF were analyzed by general linear regression versus day of culture over the first 10 days. Mortality through 18 weeks was 37% for EFA > = 0.60 (n = 170), 36% for 0.40–0.59 (n = 182), 39% for 0.30–0.39 (n = 112), 35% for 0.20–0.29 (n = 87), and 50% for those with EFA < 0.20 CFU/mL/day (n = 187). The hazard ratio for 18-week mortality, comparing those with EFA < 0.20 to those with EFA > = 0.20, was 1.60 (95% confidence interval, 1.25, 2.04; P = .002). The lowest EFA group had lower median CD4 T-cell counts (P < .01) and lower proportion of patients with CSF pleocytosis (P < .001). EFA is associated with all-cause mortality in cryptococcal meningitis. An EFA threshold of > = 0.20 log10 CFU/mL/day was associated with similar 18-week mortality (37%) compared to 50% mortality with EFA < 0.20. This EFA threshold may be considered a target for a surrogate endpoint. This builds upon existing studies to validate EFA as a surrogate endpoint.Keywords
Funding Information
- National Institute of Neurological Disorders and Stroke
- Fogarty International Center (R01NS086312, K01TW010268, R25TW009345, K43TW010718)
- National Institute of Allergy and Infectious Diseases (U01AI089244, T32AI055433)
- United Kingdom Medical Research Council
- Department of Science and Technology, Republic of South Africa (M007413/1)
- Grand Challenges Canada (S4–0296–01)
- Wellcome Trust (098316, 203135/Z/16/Z)
- National Research Foundation of South Africa (TB/HIV/AIDS-01–2014)
- South African Medical Research Council
- National Department of Health
This publication has 20 references indexed in Scilit:
- Adjunctive sertraline for HIV-associated cryptococcal meningitis: a randomised, placebo-controlled, double-blind phase 3 trialThe Lancet Infectious Diseases, 2019
- Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysisThe Lancet Infectious Diseases, 2017
- Early Fungicidal Activity as a Candidate Surrogate Endpoint for All-Cause Mortality in Cryptococcal Meningitis: A Systematic Review of the EvidencePLOS ONE, 2016
- Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging studyThe Lancet Infectious Diseases, 2016
- Funding and Innovation in Diseases of Neglected Populations: The Paradox of Cryptococcal MeningitisPLOS Neglected Tropical Diseases, 2016
- Timing of Antiretroviral Therapy after Diagnosis of Cryptococcal MeningitisNew England Journal of Medicine, 2014
- Comparison of 2 Doses of Liposomal Amphotericin B and Conventional Amphotericin B Deoxycholate for Treatment of AIDS‐Associated Acute Cryptococcal Meningitis: A Randomized, Double‐Blind Clinical Trial of Efficacy and SafetyClinical Infectious Diseases, 2010
- Independent Association between Rate of Clearance of Infection and Clinical Outcome of HIV‐Associated Cryptococcal Meningitis: Analysis of a Combined Cohort of 262 PatientsClinical Infectious Diseases, 2009
- Fungal Burden, Early Fungicidal Activity, and Outcome in Cryptococcal Meningitis in Antiretroviral-Naive or Antiretroviral-Experienced Patients Treated with Amphotericin B or FluconazoleClinical Infectious Diseases, 2007
- Comparison of Amphotericin B with Fluconazole in the Treatment of Acute AIDS-Associated Cryptococcal MeningitisNew England Journal of Medicine, 1992